Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leoni Rolfes

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 21, 2021
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes"Leoni Rolfes, Sven G Meuth
Molecular Neurobiology|April 3, 2020
NLRP3 Depletion Fails to Mitigate Inflammation but Restores Diminished Phagocytosis in BV-2 Cells After In Vitro HypoxiaIsabelle Schölwer, Pardes Habib, Clara Voelz, et al.
Journal of Neurology|January 9, 2022
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agentsMelanie Korsen, Steffen Pfeuffer, Leoni Rolfes, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 14, 2020
Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015-2020Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, et al.
Drugs|June 4, 2021
Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020Niklas Huntemann, Leoni Rolfes, Marc Pawlitzki, et al.
Ebiomedicine|June 15, 2020
Merits and culprits of immunotherapies for neurological diseases in times of COVID-19Marc Pawlitzki, Uwe K Zettl, Tobias Ruck, et al.
Therapeutic Advances in Neurological Disorders|December 26, 2022
Comparative effectiveness of natalizumab <i>versus</i> ocrelizumab in multiple sclerosis: a real-world propensity score-matched studyKatrin Pape, Leoni Rolfes, Falk Steffen, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 11, 2019
Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?Marc Pawlitzki, Tilman Schneider-Hohendorf, Leoni Rolfes, et al.
Therapeutic Advances in Neurological Disorders|March 22, 2021
Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosisSteffen Pfeuffer, Laura Kerschke, Tobias Ruck, et al.
European Journal of Neurology|November 24, 2020
Patients with a relapsing course of steroid-responsive encephalopathy associated with autoimmune thyroiditis exhibit persistent intrathecal CD4+ T-cell activationSteffen Pfeuffer, Tobias Ruck, Leoni Rolfes, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 21, 2021
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes"Leoni Rolfes, Sven G Meuth
Molecular Neurobiology|April 3, 2020
NLRP3 Depletion Fails to Mitigate Inflammation but Restores Diminished Phagocytosis in BV-2 Cells After In Vitro HypoxiaIsabelle Schölwer, Pardes Habib, Clara Voelz, et al.
Journal of Neurology|January 9, 2022
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agentsMelanie Korsen, Steffen Pfeuffer, Leoni Rolfes, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 14, 2020
Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015-2020Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, et al.
Drugs|June 4, 2021
Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020Niklas Huntemann, Leoni Rolfes, Marc Pawlitzki, et al.
Ebiomedicine|June 15, 2020
Merits and culprits of immunotherapies for neurological diseases in times of COVID-19Marc Pawlitzki, Uwe K Zettl, Tobias Ruck, et al.
Therapeutic Advances in Neurological Disorders|December 26, 2022
Comparative effectiveness of natalizumab <i>versus</i> ocrelizumab in multiple sclerosis: a real-world propensity score-matched studyKatrin Pape, Leoni Rolfes, Falk Steffen, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 11, 2019
Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?Marc Pawlitzki, Tilman Schneider-Hohendorf, Leoni Rolfes, et al.
Therapeutic Advances in Neurological Disorders|March 22, 2021
Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosisSteffen Pfeuffer, Laura Kerschke, Tobias Ruck, et al.
European Journal of Neurology|November 24, 2020
Patients with a relapsing course of steroid-responsive encephalopathy associated with autoimmune thyroiditis exhibit persistent intrathecal CD4+ T-cell activationSteffen Pfeuffer, Tobias Ruck, Leoni Rolfes, et al.
Pageof 5